BioLineRx USA, Inc.
$3.3M 137 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd. reported $3,249,733.06 across General Payments, Research, and Ownership to 133 physicians and teaching hospitals across 601 transactions.
- $3.2M Top quartile payer
- All-tracks total
- 601 Above-median volume
- Transactions
- 133 Below-median reach
- Recipients
- +$167.0K
- General Payments vs PY2023
Chugai Pharmaceutical Co., Ltd. reported $3,249,733.06 across all CMS Open Payments tracks (General + Research + Ownership) to 133 physicians and teaching hospitals in Program Year 2024 - ranking #345 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $493,967.90, averaging $24.4K per recipient.
How Chugai Pharmaceutical Co., Ltd.'s $3.2M all-tracks total breaks down
Chugai Pharmaceutical Co., Ltd.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
29/100
Total payments
F
40/100
Transaction volume
F
14/100
Physician reach
F
11/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer chugai-pharmaceutical-co-ltd Chugai Pharmaceutical Co., Ltd.
$3.2M · #345/1,925 · 0.0% industry · PY2024
- TOT $3.2M
- RANK #345
- SHARE 0.0%
- TXN 601
- RCP 133
- CAT 4
- GEN $494.0K
- ΔGEN +$167.0K
- TOP1 14.1%
- PY 2024
Volume peers
Nearest volume peer: BioLineRx USA, Inc. ($3.3M)
Chugai Pharmaceutical Co., Ltd. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Chugai Pharmaceutical Co., Ltd.'s CMS-reported General Payments increased by $167.0K (+51.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: CHUGAI PHARMACEUTICAL CO., LTD.PY2023: CHUGAI PHARMACEUTICAL CO., LTD.PY2024: Chugai Pharmaceutical Co., Ltd.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $326,957.82
- PY2024
- $493,967.90
What the Data Shows for Chugai Pharmaceutical Co., Ltd.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Chugai Pharmaceutical Co., Ltd., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 4-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $255.9K, accounting for 51.8% of this company's General Payments and 57 transactions.
General Payment Breakdown by Type
Across 4 types of general payments, Chugai Pharmaceutical Co., Ltd.'s largest category was "Consulting Fee" at $255.9K - 51.8% of General Payments.
Chugai Pharmaceutical Co., Ltd. reports 4 general-payment categories - the top three are Consulting Fee (51.8%), Travel and Lodging (37.1%), and Royalty or License (10.1%). The remaining 1 category make up 1.0% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Chugai Pharmaceutical Co., Ltd. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $255.9K | 57 | 51.8% |
| Travel and Lodging | $183.4K | 45 | 37.1% |
| Royalty or License | $50.0K | 2 | 10.1% |
| Food and Beverage | $4.7K | 29 | 1.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $191,616.64 (38.8%) of $493,967.90 in this company's General Payments records across 48 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Chugai Pharmaceutical Co., Ltd.
The five named recipients with the highest reported General Payments from this company
- 1
Christopher Flowers
$69,751.94 across 7 reported transactions
- 2
Massachusetts General Hospital
$40,000.00 across 1 reported transactions
- 3
Joseph Murray
$33,247.10 across 6 reported transactions
- 4
Norman Sharpless
$26,180.68 across 4 reported transactions
- 5
Fredrick Hagemeister
$22,436.92 across 8 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Chugai Pharmaceutical Co., Ltd. ranks #345 of 1,925 by total payments (top 18% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,261 of 1,838 by HHI (bottom 31% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Cochlear Americas : $568.5K total payments, HHI 553
- Eitan Medical North America, Inc. : $1.6K total payments, HHI 552
- Henry Schein Puerto Rico, Inc. : $2.6K total payments, HHI 552
- iotaMotion, Inc. : $37.4K total payments, HHI 552
- Lightforce Orthodontics, Inc. : $511.3K total payments, HHI 551
- DENTSPLY IH Inc. : $389.9K total payments, HHI 550
- Chugai Pharmaceutical Co., Ltd. (this company) : $494.0K total payments, HHI 550
- Novocure Inc. : $1.2M total payments, HHI 549
- Blue Surgical Llc : $12.0K total payments, HHI 549
- IBA Proton Therapy, Inc. : $24.6K total payments, HHI 548
- Rattan And Associates : $17.3K total payments, HHI 548
- Apellis Pharmaceuticals, Inc. : $3.5M total payments, HHI 546
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Chugai Pharmaceutical Co., Ltd.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Chugai Pharmaceutical Co., Ltd..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Chugai Pharmaceutical Co., Ltd..
Showing 6 of 1,924 companies with CMS-reported payment data.
Endo USA, Inc.
$3.2M 10,750 recipients
Compare payment profiles
BeiGene AUS Pty Ltd
$3.2M 0 recipients
Compare payment profiles
Phasor Health, LLC
$3.2M 0 recipients
Compare payment profiles
Kowa Holdings America, Inc.
$3.3M 0 recipients
Compare payment profiles
Viseon, Inc.
$3.2M 67 recipients
Compare payment profiles
Put this to use
Chugai Pharmaceutical Co., Ltd. ranks #345 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Chugai Pharmaceutical Co., Ltd. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Chugai Pharmaceutical Co., Ltd.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.